-
1Academic Journal
Authors: I. N. Zaborskiy, K. N. Safiullin, E. I. Smolenov, E. O. Shchukina, V. S. Chaykov, A. V. Troyanov, I. O. Dementiev, O. B. Karyakin, S. A. Ivanov, A. D. Kaprin, И. Н. Заборский, К. Н. Сафиуллин, Е. И. Смоленов, Е. О. Щукина, В. С. Чайков, А. В. Троянов, И. О. Дементьев, О. Б. Карякин, С. А. Иванов, А. Д. Каприн
Source: Cancer Urology; Том 20, № 2 (2024); 140-147 ; Онкоурология; Том 20, № 2 (2024); 140-147 ; 1996-1812 ; 1726-9776
Subject Terms: органосохраняющая лучевая терапия, muscle-invasive bladder cancer, radical cystectomy, organ-preserving radiation therapy, мышечно-инвазивный рак мочевого пузыря, радикальная цистэктомия
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1823/1543; Barringer B.S. Radium treatment of carcinoma of the bladder. Ann Surg 1921;74(6):751–67.; Orton C.G., Seyedsadr M., Somnay A. Comparison of high and low dose rate remote afterloading for cervix cancer and the importance of fractionation. Int J Radiat Oncol Biol Phys 1991;21(6):1425–34. DOI:10.1016/0360-3016(91)90316-v; Herger C., Sauer H.R. Radium treatment of cancer of bladder. Report of 267 cases. Am J Roentgenol 1942;47:909–15.; Van der Werf-Messing B. Treatment of carcinoma of the bladder with radium. Clin Radiol 1965;16:16–26. DOI:10.1016/s0009-9260(65)80029-0; Van der Werf-Messing B., Star W.M., Menon R.S. T3NXM0 carcinoma of the urinary bladder treated by the combination of radium implant and external irradiation. A preliminary report. Int J Radiat Oncol Biol Phys 1980;6(12):1723–5. DOI:10.1016/0360-3016(80)90259-x; Wijnmaalen A., van der Werf-Messing B.H. Factors influencing the prognosis in bladder cancer. Int J Radiat Oncol Biol Phys 1986;12(4):559–65. DOI:10.1016/0360-3016(86)90063-5; Morson A.C. Observations on twenty-three cases of carcinoma of the bladder treated by radium. Br Med J 1929;1(3570):1038–9. DOI:10.1136/bmj.1.3570.1038; Lenz M., Cahill G.F. The treatment of cancer of the bladder by radium needles. Am J Roentgenol Radium Ther 1947;58(4):486–92.; Barringer B.S. Twenty-five years of radon treatment of cancer of the bladder. J Am Med Assoc 1947;135(10):616–8. DOI:10.1001/jama.1947.02890100010003; Van der Werf-Messing B., Menon R.S., Hop W.C.J. Cancer of the urinary bladder category T2, T3, (NXM0) treated by interstitial radium implant: second report. Int J Radiat Oncol Biol Phys 1983;9(4):481–5. DOI:10.1016/0360-3016(83)90064-0; Van der Werf-Messing B.H., Van Putten W.L. Carcinoma of the urinary bladder category T2,3NXM0 treated by 40 Gy external irradiation followed by cesium137 implant at reduced dose (50 %). Int J Radiat Oncol Biol Phys 1989;16(2):369–71. DOI:10.1016/0360-3016(89)90332-5; Mazeron J.J., Crook J., Chopin D. et al. Conservative treatment of bladder carcinoma by partial cystectomy and interstitial iridium 192. Int J Radiat Oncol Biol Phys 1988;15(6):1323–30. DOI:10.1016/0360-3016(88)90227-1; De Neve W., Lybeert M.L., Goor C. et al. T1 and T2 carcinoma of the urinary bladder: Long term result with external, preoperative, or interstitial radiotherapy. Int J Radiat Oncol Biol Phys 1992;23(2):299–304. DOI:10.1016/0360-3016(92)90745-4; Battermann J.J., Tierie A.H. Results of implantation for T1 and T2 bladder tumours. Radiother Oncol 1986;5(2):85–90. DOI:10.1016/s0167-8140(86)80161-x; Pernot M., Hubert J., Guillemin F. et al. Combined surgery and brachytherapy in the treatment of some cancers of the bladder (partial cystectomy and interstitial iridium-192). Radiother Oncol 1996;38(2):115–20. DOI:10.1016/0167-8140(96)82354-1; Wijnmaalen A., Helle P.A., Koper P.C. et al. Muscle invasive bladder cancer treated by transurethral resection, followed by external beam radiation and interstitial iridium-192. Int J Radiat Oncol Biol Phys 1997;39(5):1043–52. DOI:10.1016/s0360-3016(97)00375-1; De Crevoisier R., Ammor A., Court B. et al. Bladder-conserving surgery and interstitial brachytherapy for lymph node negative transitional cell carcinoma of the urinary bladder: Results of a 28-year single institution experience. Radiother Oncol 2004;72(2):147–57. DOI:10.1016/j.radonc.2004.06.002; Nieuwenhuijzen J.A., Pos F., Moonen L.M.F. et al. Survival after bladder-preservation with brachytherapy versus radical cystectomy; a single institution experience. Eur Urol 2005;48(2):239–45. DOI:10.1016/j.eururo.2005.03.022; Rozan R., Albuisson E., Donnarieix D. et al. Interstitial iridium-192 for bladder cancer (A multicentric survey: 205 patients). Int J Radiat Oncol Biol Phys 1992;24(3):469–77. DOI:10.1016/0360-3016(92)91061-q; Brenner D.J., Hall E.J. Conditions for the equivalence of continuous to pulsed low dose rate brachytherapy. Int J Radiat Oncol Biol Phys 1991;20(1):181–90. DOI:10.1016/0360-3016(91)90158-z; Soete G., Coen V., Verellen D. et al. A feasibility study of high dose rate brachytherapy in solitary urinary bladder cancer. Int J Radiat Oncol Biol Phys 1997;38(4):743–7. DOI:10.1016/s0360-3016(97)00063-1; Pos F.J., Horenblas S., Lebesque J. et al. Low-dose-rate brachytherapy is superior to high-dose-rate brachytherapy for bladder cancer. Int J Radiat Oncol Biol Phys 2004;59(3):696–705. DOI:10.1016/j.ijrobp.2003.11.040; Blank L.E.C.M., Koedooder K., van Os R. et al. Results of bladderconserving treatment, consisting of brachytherapy combined with limited surgery and external beam radiotherapy, for patients with solitary T1-T3 bladder tumors less than 5 cm in diameter. Int J Radiat Oncol Biol Phys 2007;69(2):454–8. DOI:10.1016/j.ijrobp.2007.03.014; Koning C.C.E.,Blank L.E.C.M., Koedooder C. et al. Brachytherapy after external beam radiotherapy and limited surgery preserves bladders for patients with solitary pT1-pT3 bladder tumors. Ann Oncol 2012;23(11):2948–53. DOI:10.1093/annonc/mds126; Smits G.A.H.J., Van der Steen-Banasik E., Oosterveld B. et al. Minimal invasive surgery and brachytherapy as bladder preserving multimodality treatment in selected solitary MIBC. Eur Urol Suppl 2019;18(1):e814. DOI:10.1016/S1569-9056(19)30594-9; Van der Steen-Banasik E.M., Smits G.A.H.J., Oosterveld B.J. et al. The Curie-Da Vinci connection: 5-years’ experience with laparoscopic (robot-assisted) implantation for high-dose-rate brachytherapy of solitary T2 bladder tumors. Int J Radiat Oncol Biol Phys 2016;95(5):1439–42. DOI:10.1016/j.ijrobp.2016.03.029; Bus S.J.E.A., Leus N.G., Oosterveld B.J. et al. An evaluation of our experience in position verification of catheters used for interstitial high-dose-rate brachytherapy of solitary bladder tumors. Brachytherapy 2018;17(1):24–30. DOI:10.1016/j.brachy.2017.01.013; Voskuilen C.S., Bosschieter J., van Werkhoven E. et al. Long-term survival and complications following bladder-preserving brachytherapy in patients with cT1-T2 bladder cancer. Radiother Oncol 2019;141:130–6. DOI:10.1016/j.radonc.2019.09.026; Van Onna I.E.W., Oddens J.R., Kok E.T. et al. External beam radiation therapy followed by interstitial radiotherapy with iridium-192 for solitary bladder tumours: results of 111 treated patients. Eur Urol 2009;56(1):113–22. DOI:10.1016/j.eururo.2008.07.043; Van der Steen-Banasik E., Ploeg M., Witjes J.A. et al. Brachytherapy versus cystectomy in solitary bladder cancer: A case control, multicentre, East-Netherlands study. Radiother Oncol 2009;93(2):352–357. DOI:10.1016/j.radonc.2009.04.020; Aluwini S., Van Rooij P.H.E., Kirkels W.J. et al. Bladder function preservation with brachytherapy, external beam radiation therapy, and limited surger in bladder cancer patients: Long-term results. Int J Radiat Oncol Biol Phys 2014;88(3):611–7. DOI:10.1016/j.ijrobp.2013.11.227; Krasnow R.E., Drumm M., Roberts H.J. et al. Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy. Eur Urol 2017;72(1):54–60. DOI:10.1016/j.eururo.2016.12.002; Han B., Liang S., Jing Y. et al. Organ preservation for muscleinvasive bladder cancer by preoperative intra-arterial chemotherapy and transurethral resection. Med Oncol 2014;31(4):912. DOI:10.1007/s12032-014-0912-9; Mak R.H., Hunt D., Shipley W.U. et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol 2014;32(34):3801–9. DOI:10.1200/JCO.2014.57.5548; Pieters B.R., Van der Steen-Banasik E., Smits G.A. et al. GEC-ESTRO/ACROP recommendations for performing bladdersparing treatment with brachytherapy for muscle-invasive bladder carcinoma. Radiother Oncol 2017;122(3):340–6. DOI:10.1016/j.radonc.2016.12.022; Richtlijn Blaascarcinoom Nederlandstalige samenvatting van de EAU guidelines on bladder cancer. Available at: http://www.nvu.nl; https://oncourology.abvpress.ru/oncur/article/view/1823
-
2Academic Journal
Authors: Navrotskyi, B.M.
Source: Practical oncology; Том 2, № 4 (2019); 40-44
Практическая онкология-Praktična onkologìâ; Том 2, № 4 (2019); 40-44
Практична онкологія-Praktična onkologìâ; Том 2, № 4 (2019); 40-44Subject Terms: тримодальна терапія раку сечового міхура, м'язово-інвазивний рак сечового міхура, парціальна цистектомія, радикальна цистектомія, трехмодальная терапия рака мочевого пузыря, мышечно-инвазивный рак мочевого пузыря, парциальная цистэктомия, радикальная цистэктомия, trimodal bladder cancer therapy, muscle invasive bladder cancer, partial cystectomy, radical cystectomy, 3. Good health
File Description: application/pdf
-
3Academic Journal
Authors: L. Yu. Grivtsova, O. B. Karyakin, M. G. Syadrin, S. M. Samborsky, S. A. Ivanov, A. D. Kaprin, Л. Ю. Гривцова, О. Б. Карякин, М. Г. Сядрин, С. М. Самборский, С. А. Иванов, А. Д. Каприн
Source: Cancer Urology; Том 19, № 2 (2023); 111-126 ; Онкоурология; Том 19, № 2 (2023); 111-126 ; 1996-1812 ; 1726-9776
Subject Terms: таргетная терапия, muscle-invasive bladder cancer, biomarker, chemotherapy, biotherapy, immunotherapy, targeted therapy, мышечно-инвазивный рак мочевого пузыря, биомаркер, химиотерапия, биотерапия, иммунотерапия
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1676/1464; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1676/1253; Bellmunt J., Théodore C., Demkov T. et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009;27(27):4454–61. DOI:10.1200/JCO.2008.20.5534; McCaffrey J.A., Hilton S., Mazumdar M. et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 1997;15(5):1853–7. DOI:10.1200/JCO.1997.15.5.1853; Szklener K., Chmiel P., Michalski A., Mańdziuk S. New directions and challenges in targeted therapies of advanced bladder cancer: the role of FGFR inhibitors. Cancers 2022;14(6):1416. DOI:10.3390/cancers14061416; Khalife N., Chahine C., Kordahi M. et al. Urothelial carcinoma in the era of immune checkpoint inhibitors. Immunotherapy 2021;13(11):953–64. DOI:10.2217/imt-2021-0042; Heath E.I., Rosenberg J.E. The biology and rationale of targeting nectin–4 in urothelial carcinoma. Nat Rev Urol 2021;18(2):93–103. DOI:10.1038/s41585-020-00394-5; Tagawa S.T., Balar A.V., Petrylak D.P. et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinumbased chemotherapy and checkpoint inhibitors abstract. J Clin Oncol 2021;39(22):2474–85. DOI:10.1200/JCO.20.03489; Powles T., Park S.H., Voog E. et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 2020;383(13):1218–30. DOI:10.1056/NEJMoa2002788; Bellmunt J., de Wit R., Vaughn D.J. et al. KEYNOTE-045 Investigators. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376(11):1015–26. DOI:10.1056/NEJMoa1613683; Powles T., Rosenberg J.E., Sonpavde G.P. et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 2021;384(12):1125–35. DOI:10.1056/NEJMoa2035807; Loriot Y., Balar A., Petrylak D. et al. LBA24 TROPHY-U-01 cohort 1 final results: a phase II study of sacituzumab govitecan (SG) in metastatic urothelial cancer (mUC) that has progressed after platinum (PLT) and checkpoint inhibitors (CPI). Ann Oncol 2020;31:1142–215.; Loriot Y., Necchi A., Park S.H. et al. BLC2001 Study Group. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med 2019;381(4):338–48. DOI:10.1056/NEJMoa1817323; Loehrer Sr P.J., Einhorn L.H., Elson P.J. et al. A randomized comparison of cisplatin alone or in combination with methotrexate,vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992;10(7):1066–73. DOI:10.1200/JCO.1992.10.7.1066; Logothetis C.J., Dexeus F.H., Finn L. et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990;8(6):1050–5. DOI:10.1200/JCO.1990.8.6.1050; Von der Maase H., Hansen S.W., Roberts J.T. et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18(17):3068–77. DOI:10.1200/JCO.2000.18.17.3068; Galsky M.D., Arija J.Á.A., Bamias A. et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2020;395(10236):1547–57. DOI:10.1016/S0140-6736(20)30230-0; Powles T., Csőszi T., Özgüroğlu M. et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol 2021;22(7):931–45. DOI:10.1016/S1470-2045(21)00152-2; Powles T., van der Heijden M.S., Castellano D. et al. Durvalumab alone and durvalumab plus tremelimumab versus hemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, openlabel, multicentre, phase 3 trial. Lancet Oncol 2020;21(12):1574–88. DOI:10.1016/S1470-2045(20)30541-6; Rosenberg J.E., Flaig T.W., Friedlander T.W. et al. Study EV-103: durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma. J Clin Oncol 2020;38:5044 (2021;39(15):4528).; Li X., Heyer W.D. Homologous recombination in DNA repair and DNA damage tolerance. Cell Res 2008;18(1):99–113. DOI:10.1038/cr.2008.1; Reardon J.T., Vaisman A., Chaney S.G., Sancar A. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-acetoammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 1999;59(16):3968–71.; Lord R.V.N., Brabender J., Gandara D. et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8(7):2286–91.; Britten R.A., Liu D., Tessier A. et al. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer 2000;89(5):453–7.; Olaussen K.A., Dunant A., Fouret P. et al. IALT Bio Investigators. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatinbased adjuvant chemotherapy. N Engl J Med 2006;355(10):983–91. DOI:10.1056/NEJMoa060570; Dabholkar M., Vionnet J., Bostick-Bruton F. et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994;94(2):703–8. DOI:10.1172/JCI117388; Metzger R., Leichman C.G., Danenberg K.D. et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998;16(1):309–16. DOI:10.1200/JCO.1998.16.1.309; Shirota Y., Stoehlmacher J., Brabender J. et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001;19(23):4298–304. DOI:10.1200/JCO.2001.19.23.4298; Klatte T., Seitz C., Rink M. et al. ERCC1 as a prognostic and predictive biomarker for urothelial carcinoma of the bladder following radical cystectomy. J Urol 2015;194(5):1456–62. DOI:10.1016/j.juro.2015.06.099; Necchi A., Lo Vullo S., Raggi D. et al. Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: an open-label, single-arm, single-center, phase 2 study. Urol Oncol 2018;36(1):8.e1–8. DOI:10.1016/j.urolonc.2017.08.020; Hemdan T., Segersten U., Malmström P. 122 ERCC1-negative tumors benefit from neoadjuvant cisplatin-based chemotherapy whereas patients with ERCC1-positive tumors do not – results from a cystectomy trial database. Eur Urol 2014;13(1):e122.; Choueiri T.K., Jacobus S., Bellmunt J. et al. Neoadjuvant dosedense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol 2014;32(18):1889–94. DOI:10.1200/JCO.2013.52.4785; Sakano S., Ogawa S., Yamamoto Y. et al. ERCC1 and XRCC1 expression predicts survival in bladder cancer patients receiving combined trimodality therapy. Mol Clin Oncol 2013;1(3):403–10. DOI:10.3892/mco.2013.85; Sun J.M., Sung J.Y., Park S.H. et al. ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy. BMC Cancer 2012;12:187. DOI:10.1186/1471-2407-12-187; Kawashima A., Takayama H., Kawamura N. et al. Co-expression of ERCC1 and Snail is a prognostic but not predictive factor of cisplatin-based neoadjuvant chemotherapy for bladder cancer. Oncol Lett 2012;4(1):15–21. DOI:10.3892/ol.2012.689; Ozcan M.F., Dizdar O., Dincer N. et al. Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum–based neoadjuvant chemotherapy. Urol Oncol 2013;31(8):1709–15. DOI:10.1016/j.urolonc.2012.06.014; Nikitas N., Karadimou A., Tsitoura E. et al. Association of ERCC1 SNPs with outcome in platinum–treated patients with advanced urothelial cancer: a Hellenic Cooperative Oncology Group study. Pharmacogenomics 2012;13(14):1595–607. DOI:10.2217/pgs.12.162; Kim K.H., Do I.G., Kim H.S. et al. Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin–based chemotherapy. APMIS 2010;118(12):941–8. DOI:10.1111/j.1600-0463.2010.02648.x; Hoffmann A.C., Wild P., Leicht C. et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 2010;12(8):628–36. DOI:10.1593/neo.10402; Bellmunt J., Paz-Ares L., Cuello M. et al. Spanish Oncology Genitourinary Group. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007;18(3):522–8. DOI:10.1093/annonc/mdl435; Urun Y., Leow J.J., Fay A.P. et al. ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2017;120:120–6. DOI:10.1016/j.critrevonc.2017.10.012; Li Q., Damish A.W., Frazier Z. et al. ERCC2 helicase domain mutations confer nucleotide excision repair deficiency and drive cisplatin sensitivity in muscle–invasive bladder cancer. Clin Cancer Res 2019;25(3):977–88. DOI:10.1158/1078-0432.CCR-18-1001; Van Allen E.M., Mouw K.W., Kim P. et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 2014;4(10):1140–53. DOI:10.1158/2159-8290.CD-14-0623; Liu D., Plimack E.R., Hoffman-Censits J. et al. Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma. JAMA Oncol 2016;2(8):1094–6. DOI:10.1001/jamaoncol.2016.1056; Christensen E., Birkenkamp-Demtröder K., Sethi H. et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J Clin Oncol 2019;37(18):1547–57. DOI:10.1200/JCO.18.02052; Groenendijk F.H., de Jong J., Fransen van de Putte E.E. et al. ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur Urol 2016;69(3):384–8. DOI:10.1016/j.eururo.2015.01.014; Groenendijk F.H., Fransen van de Putte E.E., van Rhijn B.W. et al. Garraway and Jonathan E. Rosenberg’s Letter to the Editor re: Groenendijk F.H., de Jong J., Fransen van de Putte E.E. et al. ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur Urol 2015;68(2):e33–4.; Taber A., Christensen E., Lamy P. et al. Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multiomics analysis. Nat Commun 2020;11(1):4858. DOI:10.1038/s41467-020-18640-0; Kim J., Mouw K.W., Polak P. et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat Genet 2016;48(6):600–6. DOI:10.1038/ng.3557; Galsky M.D., Daneshmand S., Chan K.G. et al. Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer (MIBC): HCRN GU16-257. J Clin Oncol 2021;39:4503.; Yang D., Khan S., Sun Y. et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011;306(14):1557–65. DOI:10.1001/jama.2011.1456; Sakai W., Swisher E.M., Karlan B.Y. et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008;451(7182):1116–20. DOI:10.1038/nature06633; Tutt A., Tovey H., Cheang M.C.U. et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med 2018;24(5):628–37. DOI:10.1038/s41591-018-0009-7; Robertson A.G., Kim J., Al-Ahmadie H. et al. TCGA Research Network. Comprehensive molecular characterization of muscleinvasive bladder cancer. Cell 2017;171(3):540–56.e25.; Carlo M.I., Ravichandran V., Srinavasan P. et al. Cancer susceptibility mutations in patients with urothelial malignancies. J Clin Oncol 2020;38(5):406–14. DOI:10.1200/JCO.19.01395; Nassar A.H., Abou Alaiwi S., AlDubayan S.H. et al. Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma. Genet Med 2020;22(4):709–18. DOI:10.1038/s41436-019-0720-x; Mullane S.A., Werner L., Guancial E.A. et al. Expression levels of DNA damage repair proteins are associated with overall survival in platinum-treated advanced urothelial carcinoma. Clin Genitourin Cancer 2016;14(4):352–9. DOI:10.1016/j.clgc.2015.12.029; Lord C.J., Ashworth A. RAD51, BRCA2 and DNA repair: a partial resolution. Nat Struct Mol Biol 2007;14(6):461–2. DOI:10.1038/nsmb0607-461; Plimack E.R., Dunbrack R.L., Brennan T.A. et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur Urol 2015;68(6):959–67. DOI:10.1016/j.eururo.2015.07.009; Miron B., Ross E.A., Anari F. et al. Defects in DNA repair genes and long-term survival in cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer (MIBC). J Clin Oncol 2019;37:4536.; Teo M.Y., Bambury R.M., Zabor E.C. et al. DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma. Clin Cancer Res 2017;23(14):3610–8. DOI:10.1016/j.urolonc.2018.05.011; Rosenberg J.E., Ballman K.A., Halabi S. et al. Randomized phase III trial of gemcitabine and cisplatin with bevacizumab or placebo in patients with advanced urothelial carcinoma: results of CALGB 90601 (Alliance). J Clin Oncol 2021;39(22):2486–96. DOI:10.1200/JCO.21.00286; Geynisman D.M., Abbosh P., Ross E.A. et al. A phase II trial of risk enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN BLADDER): interim analysis. J Clin Oncol 2021;39(6):397.; Powles T., Loriot Y., Bellmunt J. et al. 699O avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC): association between clinical outcomes and exploratory biomarkers. Ann Oncol 2020;31(4):552–3. DOI:10.1016/j.annonc.2020.08.771; Powles T., Assaf Z.J., Davarpanah N. et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature 2021;595(7867): 432–7. DOI:10.1038/s41586-021-03642-9; Bellmunt J., Hussain M., Gschwend J.E. et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2021;22(4):525–37. DOI:10.1016/S1470-2045(21)00004-8; Kamoun A., de Reyniès A., Allory Y. et al. Bladder Cancer Molecular Taxonomy Group. A consensus molecular classification of muscleinvasive bladder cancer. Eur Urol 2020;77(4):420–33. DOI:10.1016/j.eururo.2019.09.006; Wang L., Gong Y., Saci A. et al. Fibroblast growth factor receptor 3 alterations and response to PD-1/PD-L1 blockade in patients with metastatic urothelial cancer. Eur Urol 2019;76(5):599–603. DOI:10.1016/j.eururo.2019.06.025; Rose T.L., Weir W.H., Mayhew G.M. et al. Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience. Br J Cancer 2021;125(9):1251–60. DOI:10.1038/s41416-021-01488-6; Powles T., Carroll D., Chowdhury S. et al. An adaptive, biomarkerdirected platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. Nat Med 2021;27(5):793–801. DOI:10.1038/s41591-021-01317-6; Sharma P., Retz M., Siefker-Radtke A. et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2017;18(3):312–22. DOI:10.1016/S1470-2045(17)30065-7; Powles T., O’Donnell P.H., Massard C. et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 Open-label study. JAMA Oncol 2017;3(9):e172411. DOI:10.1001/jamaoncol.2017.2411; FDA alerts health care professionals and oncology clinical investigators about an efficacy issue identified in clinical trials for some patients taking keytruda (pembrolizumab) or tecentriq (atezolizumab) as monotherapy to treat urothelial cancer with low expression of PD-L1. Available at: https://www.fda.gov/drugs/drugsafety-and-availability/fda-alerts-health-care-professionals-andoncologyclinical-investigators-about-efficacy-issue.; Galsky M.D., Necchi A., Sridhar S.S. et al. A phase III, randomized, open-label, multicenter, global study of first-line durvalumab plus standard of care (SoC) chemotherapy and durvalumab plus tremelimumab, and SoC chemotherapy versus SoC chemotherapy alone in unresectable locally advanced or metastatic urothelial cancer (NILE). J Clin Oncol 2021;39(6):TPS504. DOI:10.1200/JCO.2021.39.6_suppl.TPS504; Rui X., Gu T.T., Pan H.F., Zhang H.Z. Evaluation of PD-L1 biomarker for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatments for urothelial carcinoma patients: a metaanalysis. Int Immunopharmacol 2019;67:378–85. DOI:10.1016/j.intimp.2018.12.018; Litchfield K., Reading J.L., Puttick C. et al. Meta-analysis of tumorand T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 2021;184(3):596–614.e14. DOI:10.1016/j.cell.2021.01.002; Powles T., Durán I., van der Heijden M.S. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018;391(10122):748–57. DOI:10.1016/S0140-6736(17)33297-X; Hirsch F.R., McElhinny A., Stanforth D. et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol 2017;12(2):208–22. DOI:10.1016/j.jtho.2016.11.2228; Ratcliffe M.J., Sharpe A., Midha A. et al. Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer. Clin Cancer Res 2017;23(14):3585–91. DOI:10.1158/1078-0432.CCR-16-2375; Tsao M.S., Kerr K.M., Kockx M. et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol 2018;13(9):1302–11. DOI:10.1016/j.jtho.2018.05.013; Decazes P., Bohn P. Immunotherapy by immune checkpoint inhibitors and nuclear medicine imaging: current and future applications. Cancers (Basel) 2020;12(2):371. DOI:10.3390/cancers12020371; Bensch F., van der Veen E.L., Lub-de Hooge M.N. et al. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med 2018;24(12):1852–8. DOI:10.1038/s41591-018-0255-8; Niemeijer A.N., Leung D., Huisman M.C. et al. Whole body PD-1 and PD-L1 positron emission tomography in patients with nonsmallcell lung cancer. Nat Commun 2018;9(1):4664. DOI:10.1038/s41467-018-07131-y; Alexandrov L.B., Nik-Zainal S., Wedge D.C. et al. Signatures of mutational processes in human cancer. Nature 2013;500(7463): 415–21. DOI:10.1016/j.celrep.2012.12.008; Rosenberg J.E., Hoffman-Censits J., Powles T. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387(10031):1909–20. DOI:10.1016/S0140-6736(16)00561-4; Samstein R.M., Lee C.H., Shoushtari A.N. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 2019;51(2):202–6. DOI:10.1038/s41588-018-0312-8; Mariathasan S., Turley S.J., Nickles D. et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 2018;554(7693):544–8. DOI:10.1038/nature25501; Bellmunt J., de Wit R., Fradet Y. et al. 747P association of TMB with efficacy of pembrolizumab (pembro) in patients (pts) with advanced urothelial cancer (UC): results from KEYNOTE-045 and KEYNOTE-052. Ann Oncol 2020;31(suppl 4):580–1. DOI:10.1016/j.annonc.2020.08.819; FDA approves pembrolizumab for adults and children with TMB-H solid tumors. Available at: https://www.fda.gov/drugs/drugapprovals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors.; Yarchoan M., Albacker L.A., Hopkins A.C. et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight 2019;4(6):126908. DOI:10.1172/jci.insight.126908; Galsky M.D., Saci A., Szabo P.M. et al. Nivolumab in patients with advanced platinum-resistant urothelial carcinoma: efficacy, safety, and biomarker analyses with extended follow-up from checkmate 275. Clin Cancer Res 2020;26(19):5120–8. DOI:10.1158/1078-0432.CCR-19-416; Galsky M.D., Banchereau R., Hamidi H.R. et al. Tumor, immune, and stromal characteristics associated with clinical outcomes with atezolizumab (atezo) + platinum-based chemotherapy (PBC) or atezo monotherapy (mono) versus PBC in metastatic urothelial cancer (mUC) from the phase III IMvigor130 study. J Clin Oncol 2020;38:5011. DOI:10.1200/JCO.2020.38.15_suppl.5011; Valero C., Lee M., Hoen D. et al. Response rates to anti-PD-1 Immunotherapy in microsatellite-stable solid tumors with 10 or more mutations per megabase. JAMA Oncol 2021;7(5):739–43. DOI:10.1001/jamaoncol.2020.7684; McGranahan N., Rosenthal R., Hiley C.T. et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell 2017;171(6):1259–71.e11. DOI:10.1016/j.cell.2017.10.001; Zhang J., Bu X., Wang H. et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature 2018;553(7686):91–5. DOI:10.1038/nature25015; Wang L., Saci A., Szabo P.M. et al. EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nat Commun 2018;9(1):3503. DOI:10.1038/s41467-018-05992-x; Calon A., Lonardo E., Berenguer-Llergo A. et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet 2015;47(4):320–9. DOI:10.1038/ng.3225; Massagué J. TGFbeta in cancer. Cell 2008;134(2):215–30. DOI:10.1016/j.cell.2008.07.001; Lin R.L., Zhao L.J. Mechanistic basis and clinical relevance of the role of transforming growth factor-β in cancer. Cancer Biol Med 2015;12(4):385–93. DOI:10.7497/j.issn.2095-3941.2015.0015; O’Donnell P.H., Grivas P., Balar A.V. et al. Biomarker findings and mature clinical results from KEYNOTE-052: first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC). J Clin Oncol 2017;35:4502. DOI:10.1200/JCO.2017.35.15_SUPPL.4502; Chen B., Khodadoust M.S., Liu C.L. et al. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol 2018;1711:243–59. DOI:10.1007/978-1-4939-7493-1_12; Aran D., Hu Z., Butte A.J. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol 2017;18(1):220. DOI:10.1186/s13059-017-1349-1; Cao J., Yang X., Li J. et al. Screening and identifying immunerelated cells and genes in the tumor microenvironment of bladder urothelial carcinoma: based on TCGA database and bioinformatics. Front Oncol 2019;9:1533. DOI:10.3389/fonc.2019.01533; Gohil S.H., Iorgulescu J.B., Braun D.A. et al. Applying highdimensional single-cell technologies to the analysis of cancer immunotherapy. Nat Rev Clin Oncol 2021;18(4):244–56. DOI:10.1038/s41571-020-00449-x; Guruprasad P., Lee Y.G., Kim K.H., Ruella M. The current landscape of single-cell transcriptomics for cancer immunotherapy. J Exp Med 2021;218(1):e20201574. DOI:10.1084/jem.20201574; Oh D.Y., Kwek S.S., Raju S.S. et al. Intratumoral CD4+ T cells mediate anti-tumor cytotoxicity in human bladder cancer. Cell 2020;181(7):1612–25.e13. DOI:10.1016/j.cell.2020.05.017; Chen Z., Zhou L., Liu L. et al. Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma. Nat Commun 2020;11(1):5077. DOI:10.1038/s41467-020-18916-5; Sfakianos J.P., Daza J., Hu Y. et al. Epithelial plasticity can generate multi-lineage phenotypes in human and murine bladder cancers. Nat Commun 2020;11(1):2540. DOI:10.1038/s41467-020-16162-3; Mota J.M., Leite C.A., Souza L.E. et al. Post-sepsis state induces tumor-associated macrophage accumulation through CXCR4/CXCL12 and favors tumor progression in mice. Cancer Immunol Res 2016;4(4):312–22. DOI:10.1158/2326-6066.CIR-15-0170; Wang L., Sfakianos J.P., Beaumont K.G. et al. Myeloid cell-associated resistance to PD-1/PD-L1 blockade in urothelial cancer revealed through bulk and single-cell RNA sequencing. Clin Cancer Res 2021;27(15):4287–300. DOI:10.1158/1078-0432.CCR-20-4574; Siefker-Radtke A.O., Necchi A., Park S.H. et al. ERDAFITINIB in locally advanced or metastatic urothelial carcinoma (mUC): long-term outcomes in BLC2001. J Clin Oncol 2020;38(15):5015. DOI:10.1200/JCO.2020.38.15_suppl.5015; Challita-Eid P.M., Satpayev D., Yang P. et al. Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res 2016;76(10):3003–13. DOI:10.1158/0008-5472.CAN-15-1313; Doronina S.O., Toki B.E., Torgov M.Y. et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21(7):778–84. DOI:10.1038/nbt832; Itoh N., Ornitz D.M. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem 2011;149(2):121–30. DOI:10.1093/jb/mvq121; Plotnikov A.N., Schlessinger J., Hubbard S.R., Mohammadi M. Structural basis for FGF receptor dimerization and activation. Cell 1999;98(5):641–50. DOI:10.1016/s0092-8674(00)80051-3; Dieci M.V., Arnedos M., Andre F., Soria J.C. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov 2013;3(3):264–79. DOI:10.1158/2159-8290.CD-12-0362; Di Martino E., Tomlinson D.C., Knowles M.A. A decade of FGF receptor research in bladder cancer: past, present, and future challenges. Adv Urol 2012;2012:429213. DOI:10.1155/2012/429213; Helsten T., Elkin S., Arthur E. et al. The FGFR landscape in cancer: analysis of 4,853 tumors by nextgeneration sequencing. Clin Cancer Res 2016;22(1):259–67. DOI:10.1158/1078-0432.CCR-14-3212; Costa R., Carneiro B.A., Taxter T. et al. FGFR3-TACC3 fusion in solid tumors: mini review. Oncotarget 2016;7(34):55924–38. DOI:10.1158/1078-0432.CCR-14-3212; Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507(7492):315–22. DOI:10.1038/nature12965; Siefker-Radtke A., Loriot Y., Siena S. et al. 752P Updated data from the NORSE trial of erdafitinib (ERDA) plus cetrelimab (CET) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and specific fibroblast growth factor receptor (FGFR) alterations. Ann Oncol 2020;31:584–5. DOI:10.1016/j.annonc.2020.08.824; Pal S.K., Rosenberg J.E., Hoffman-Censits J.H. et al. Efficacy of BGJ398, a fibroblast growth factor receptor 1–3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations. Cancer Discov 2018;8(7):812–21. DOI:10.1158/2159-8290.CD-18-0229; Bellmunt J., Picus J., Kohli M. et al. FIERCE-21: phase 1b/2 study of docetaxel + b-701, a selective inhibitor of FGFR3, in relapsed or refractory (R/R) metastatic urothelial carcinoma (mUCC). J Clin Oncol 2018;36:4534.; Necchi A., Castellano D.E., Mellado B. et al. Fierce-21: Phase II study of vofatmab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC). J Clin Oncol 2019;37:409.; Siefker-Radtke A.O., Currie G., Abella E. et al. FIERCE-22: clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis. J Clin Oncol 2019;37:4511. DOI:10.1200/JCO.2019.37.15_SUPPL.4511; Abdul-Karim R.M., Chaudhry A., Patrikidou A. et al. Derazantinib (DZB) in combination with atezolizumab (AZB) in patients with solid tumors: results from the dose-finding phase Ib substudy of FIDES-02. J Clin Oncol 2021;39:437. DOI:10.1200/JCO.2021.39.6_suppl.437; Chaudhry A., Sternberg C.N., De Santis M. et al. FIDES-02, a phase Ib/II study of derazantinib (DZB) as monotherapy and combination therapy with atezolizumab (A) in patients with surgically unresectable or metastaticurothelial cancer (UC) and FGFR genetic aberrations. J Clin Oncol 2020;38:TPS590. DOI:10.1200/JCO.2020.38.6_suppl.TPS590; Quinn D.I., Petrylak D.P., Bellmunt J. et al. FORT-1: phase II/III study of rogaratinib versus chemotherapy (CT) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) selected based on FGFR1/3 mRNA expression. J Clin Oncol 2020;38:489.; Rosenberg J.E., Gajate P., Morales-Barrera R. et al. Safety and preliminary efficacy of rogaratinib in combination with atezolizumab in a phase Ib/II study (FORT-2) of first-line treatment in cisplatinineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression. J Clin Oncol 2020;38(15_suppl):5014. DOI:10.1200/JCO.2020.38.15_suppl.5014; Yue S., Li Y., Chen X. et al. FGFR–TKI resistance in cancer: current status and perspectives. J Hematol Oncol 2021;14(1):23. DOI:10.1186/s13045-021-01040-2; Goyal L., Saha S.K., Liu L.Y. et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov 2017;7(3):252–63. DOI:10.1158/2159-8290.CD-16-1000; Datta J., Damodaran S., Parks H. et al. Akt activation mediates acquired resistance to fibroblast growth factor receptor inhibitor BGJ398. Mol Cancer Ther 2017;16(4):614–24. DOI:10.1158/1535-7163.MCT-15-1010; Wang L., Šuštić T., Leite de Oliveira R. et al. A functional genetic screen identifies the phosphoinositide 3-kinase pathway as a determinant of resistance to fibroblast growth factor receptor inhibitors in FGFR mutant urothelial cell carcinoma. Eur Urol 2017;71(6):858–62. DOI:10.1016/j.eururo.2017.01.021; Ryan M.R., Sohl C.D., Luo B., Anderson K.S. The FGFR1 V561M gatekeeper mutation drives AZD4547 resistance through STAT3 activation and EMT. Mol Cancer Res 2019;17(2):532–43. DOI:10.1158/1541-7786.MCR-18-0429; Mandai K., Rikitake Y., Mori M., Takai Y. Nectins and nectin-like molecules in development and disease. Curr Top Dev Biol 2015;112:197–231. DOI:10.1016/bs.ctdb.2014.11.019; Chu C.E., Sjöström M., Egusa E.A. et al. Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin. Clin Cancer Res 2021;27(18):5123–30. DOI:10.1158/1078-0432.CCR-20-4175; Hoffman-Censits J.H., Lombardo K.A., Parimi V. et al. Expression of nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes. Appl Immunohistochem Mol Morphol 2021;29(8):619–25. DOI:10.1097/PAI.0000000000000938; Rapani E., Sacchetti A., Corda D., Alberti S. Human TROP-2 is a tumor-associated calcium signal transducer. Int J Cancer 1998;76(5):671–6. DOI:10.1002/(sici)1097-0215(19980529)76:53.0.co;2-7; Faltas B., Goldenberg D.M., Ocean A.J. et al. Sacituzumab govitecan, a novel antibody – drug conjugate, in patients with metastatic platinum-resistant urothelial carcinoma. Clin Genitourin Cancer 2016;14(1):e75–9. DOI:10.1016/j.clgc.2015.10.002; Hurvitz S.A., Tolaney S.M., Punie K. et al. Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Cancer Res 2021;81:Abstract GS3–6.; Grivas P., Tagawa S.T., Bellmunt J. et al. TROPiCS-04: study of sacituzumab govitecan in metastatic or locally advanced unresectable urothelial cancer that has progressed after platinum and checkpoint inhibitor therapy. J Clin Oncol 2021;39:TPS498.; Drakaki A., Rezazadeh Kalebasty A., Lee J. et al. Phase Ib/II umbrella trial to evaluate the safety and efficacy of multiple 2L cancer immunotherapy (CIT) combinations in advanced/metastatic urothelial carcinoma (mUC): MORPHEUS-mUC. J Clin Oncol 2020;38:TPS591.; Iqbal N., Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int 2014;2014:852748. DOI:10.1155/2014/852748; Coogan C.L., Estrada C.R., Kapur S., Bloom K.J. HER-2/neu protein overexpression and gene amplification in human transitional cellcarcinoma of the bladder. Urology 2004;63(4):786–90. DOI:10.1016/j.urology.2003.10.040; Latif Z., Watters A.D., Dunn I. et al. HER2/neu overexpression in the development of muscleinvasive transitional cell carcinoma of the bladder. Br J Cancer 2003;89(7):1305–9. DOI:10.1038/sj.bjc.6601245; Choudhury N.J., Campanile A., Antic T. et al. Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB alterations. J Clin Oncol 2016;34(18):2165–71. DOI:10.1200/JCO.2015.66.3047; Font Pous A., Puente J., Castellano D.E. et al. Phase II trial of afatinib in patients with advanced/metastatic urothelial carcinoma (UC) with genetic alterations in ERBB receptors 1–3 who failed on platinum-based chemotherapy (CT). J Clin Oncol 2018;36(6):TPS540. DOI:10.1200/JCO.2018.36.6_suppl.TPS540; Hainsworth J.D., Meric-Bernstam F., Swanton C. et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol 2018;36(6):536–42. DOI:10.1200/JCO.2017.75.3780; Sheng X., Zhou A., Yao X. et al. A phase II study of RC48-ADC in HER2-positive patients with locally advanced or metastatic urothelial carcinoma. J Clin Oncol 2019;37(15_suppl):4509. DOI:10.1200/JCO.2019.37.15_suppl.4509; Bob T., Makker V., Buonocore D.J. et al. A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers. J Clin Oncol 2018;36(15_suppl):2502. DOI:10.1200/JCO.2018.36.15_suppl.2502; Duan Y., Haybaeck J., Yang Z. Therapeutic potential of PI3K/AKT/mTOR pathway in gastrointestinal stromal tumors: rationale and progress. Cancers (Basel) 2020;12(10):2972. DOI:10.3390/cancers12102972; Sathe A., Nawroth R. Targeting the PI3K/AKT/mTOR pathway in bladder cancer. Methods Mol Biol 2018;1655:335–50. DOI:10.1007/978-1-4939-7234-0_23; Iyer G., Al-Ahmadie H., Schultz N. et al. Prevalence and cooccurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol 2013;31(25):3133–40. DOI:10.1200/JCO.2012.46.5740; Platt F.M., Hurst C.D., Taylor C.F. et al. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res 2009;15(19):6008–17. DOI:10.1158/1078-0432.CCR-09-0898; Calderaro J., Rebouissou S., de Koning L. et al. PI3K/AKT pathway activation in bladder carcinogenesis. Int J Cancer 2014;134(8):1776–84. DOI:10.1002/ijc.28518; Cappellen D., Gil Diez de Medina S., Chopin D. et al. Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder. Oncogene 1997;14(25):3059–66. DOI:10.1038/sj.onc.1201154; Aveyard J.S., Skilleter A., Habuchi T., Knowles M.A. Somatic mutation of PTEN in bladder carcinoma. Br J Cancer 1999;80(5–6):904–8. DOI:10.1038/sj.bjc.6690439; Tsuruta H., Kishimoto H., Sasaki T. et al. Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients. Cancer Res 2006;66(17):8389–96. DOI:10.1158/0008-5472.CAN-05-4627; Knowles M.A., Habuchi T., Kennedy W., Cuthbert-Heavens D. Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. Cancer Res 2003;63(22):7652–6.; Milowsky M.I., Iyer G., Regazzi A.M. et al. Phase II study of everolimus in metastatic urothelial cancer. BJU Int 2013;112(4):462–70. DOI:10.1111/j.1464-410X.2012.11720.x; Bellmunt J., Lalani A.A., Jacobus S. et al. Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. Br J Cancer 2018;119(6):707–12. DOI:10.1038/s41416-018-0261-0; Wagle N., Grabiner B.C., van Allen E.M. et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov 2014;4(5):546–53. DOI:10.1158/2159-8290.CD-13-0353; Kim J.W., Milowsky M.I., Hahn N.M. et al. Sapanisertib, a dual mTORC1/2 inhibitor, for TSC1- or TSC2-mutated metastatic urothelial carcinoma (mUC). J Clin Oncol 2021;39(6):431.; McPherson V., Reardon B., Bhayankara A. et al. A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma. Cancer 2020;126(20):4532–44. DOI:10.1002/cncr.33071; Flaherty K.T., Gray R.J., Chen A.P. et al. NCI-MATCH team. Molecular landscape and actionable alterations in a genomically guided cancer clinical trial: national cancer institute molecular analysis for therapy choice (NCI-MATCH). J Clin Oncol 2020;38(33):3883–94. DOI:10.1200/JCO.19.03010; Sathe A., Guerth F., Cronauer M.V. et al. Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy. Br J Cancer 2014;111(11):2103–13. DOI:10.1038/bjc.2014.534; Dickstein R.J., Nitti G., Dinney C.P. et al. Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells. Cancer Biol Ther 2012;13(13):1325–38. DOI:10.4161/cbt.21793; Seront E., Rottey S., Filleul B. et al. Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma. BJU Int 2016;118(3):408–15. DOI:10.1111/bju.13415; Munster P., Aggarwal R., Hong D. et al. First-in-human phase I study of GSK2126458, an oral pan-class I phosphatidylinositol-3-kinase inhibitor, in patients with advanced solid tumor malignancies. Clin Cancer Res 2016;22(8):1932–9. DOI:10.1158/1078-0432.CCR-15-1665; Apolo A.B., Nadal R., Tomita Y. et al. Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an openlabel, single-centre, phase 2 trial. Lancet Oncol 2020;21(8):1099–109. DOI:10.1016/S1470-2045(20)30202-3; Apolo A.B., Nadal R., Girardi D.M. et al. Phase I study of cabozantinib and nivolumab alone or with ipilimumab for advanced or metastatic urothelial carcinoma and other genitourinary tumors. J Clin Oncol 2020;38(31):3672–84. DOI:10.1200/JCO.20.01652; https://oncourology.abvpress.ru/oncur/article/view/1676
-
4Academic Journal
Authors: Pavlov V.N., Urmantsev M.F., Korelov Y.A., Bakeev M.R.
Source: Advances in Molecular Oncology; Vol 9, No 3 (2022); 8-14 ; Успехи молекулярной онкологии; Vol 9, No 3 (2022); 8-14 ; 2413-3787 ; 2313-805X
Subject Terms: tumor associated macrophages, muscle-invasive bladder cancer, non- muscle-invasive bladder cancer, tumor microenvironment, cancerogenesis, макрофаги, ассоциированные с опухолью, мышечно-инвазивный рак мочевого пузыря, немышечно-инвазивный рак мочевого пузыря, микроокружение опухоли, канцерогенез
File Description: application/pdf
Relation: https://umo.abvpress.ru/jour/article/view/462/274; https://umo.abvpress.ru/jour/article/view/462
-
5Academic Journal
Authors: R. V. Novikov, S. N. Novikov, A. I. Novikov, S. B. Petrov, S. A. Protsenko, V. V. Protoshchak, S. V. Popov, M. I. Shkolnik, E. S. Shpilenya, A. V. Kurenkov, V. P. Sokurenko, R. V. Orlova, А. K. Nosov, V. D. Korol, D. Kh. Latipova, Yu. V. Mikheeva, S. V. Kanaev, Р. В. Новиков, С. Н. Новиков, А. И. Новиков, С. Б. Петров, С. А. Проценко, В. В. Протощак, С. В. Попов, М. И. Школьник, Е. С. Шпиленя, А. В. Куренков, В. П. Сокуренко, Р. В. Орлова, А. К. Носов, В. Д. Король, Д. Х. Латипова, Ю. В. Михеева, С. В. Канаев
Source: Cancer Urology; Том 18, № 2 (2022); 142-163 ; Онкоурология; Том 18, № 2 (2022); 142-163 ; 1996-1812 ; 1726-9776
Subject Terms: химиотерапия, bladder cancer, muscle-invasive bladder cancer, trimodal therapy, organ-sparing treatment, transurethral resection, radiotherapy, chemotherapy, рак мочевого пузыря, мышечно-инвазивный рак мочевого пузыря, тримодальная терапия, органосохраняющее лечение, трансуретральная резекция, лучевая терапия
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1534/1375; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1534/1087; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1534/1088; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1534/1089; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1534/1090; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1534/1091; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1534/1092; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1534/1093; Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020. 252 с.; Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70(1):7–30. DOI:10.3322/caac.21590; Cumberbatch M.G.K., Jubber I., Black P.C. et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol 2018;74(6):784–95. DOI:10.1016/j.eururo.2018.09.001; Rodrigues Pessoa R., Mueller A.C., Boxley P. et al. Systematic review and meta‑analysis of radiation therapy for high‑risk non‑muscle invasive bladder cancer. Urol Oncol 2021;39(11):786.e1–8. DOI:10.1016/j.urolonc.2021.03.009; Witjes J.A., Bruins H.M., Cathomas R. et al. European Association of Urology guidelines on muscle‑invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol 2021;79(1):82–104. DOI:10.1016/j.eururo.2020.03.055; Chang S.S., Bochner B.H., Chou R. et al. Treatment of non‑metastatic muscle‑invasive bladder cancer: AUA/ASCO/ASTRO/ SUO Guideline. J Urol 2017;198(3):552–9. DOI:10.1016/j.juro.2017.04.086; Flaig T.W., Spiess P.E., Agarwal N. et al. Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2020;18(3):329–54. DOI:10.6004/jnccn.2020.0011; Witjes J.A., Babjuk M., Bellmunt J. et al. EAU‑ESMO consensus statements on the management of advanced and variant bladder cancer – an international collaborative multistakeholder effort: under the auspices of the EAU‑ESMO guidelines committees. Eur Urol 2020;77(2):223–50. DOI:10.1016/j.eururo.2019.09.035; Choi H., Park J.Y., Bae J.H., Tae B.S. Health‑related quality of life after radical cystectomy. Transl Androl Urol 2020;9(6):2997–3006. DOI:10.21037/tau.2020.02.01; Hautmann R.E., de Petriconi R.C., Volkmer В.G. Lessons learned from 1,000 neobladders: the 90‑day complication rate. J Urol 2010;184(3):990–4. DOI:10.1016/j.juro.2010.05.037; Nielsen M.E., Mallin K., Weaver M.A. et al. Association of hospital volume with conditional 90‑day mortality after cystectomy: an analysis of the National Cancer Data Base. BJU Int 2014;114(1):46–55. DOI:10.1111/bju.12566; Maffezzini M., Fontana V., Pacchetti A. et al. Age above 70 years and Charlson Comorbidity Index higher than 3 are associated with reduced survival probabilities after radical cystectomy for bladder cancer. Data from a contemporary series of 334 consecutive patients. Arch Ital Urol Androl 2021;93(1):15–20. DOI:10.4081/aiua.2021.1.15; Novotny V., Froehner M., Koch R. et al. Age, American Society of Anesthesiologists physical status classification and Charlson score are independent predictors of 90‑day mortality after radical cystectomy. World J Urol 2016;34(8):1123–9. DOI:10.1007/s00345‑015‑1744‑8; Howlader N., Noone A.M., Krapcho M. et al. (2017) SEER cancer statistics review, 1975–2014. National Cancer Institute, Bethesda, MD. Available at: https://seer.cancer.gov/csr/1975_2014.; Kimura T., Ishikawa H., Kojima T. et al. Bladder preservation therapy for muscle invasive bladder cancer: the past, present and future. Jpn J Clin Oncol 2020;50(10):1097–107. DOI:10.1093/jjco/hyaa155; Varughese M., Treece S., Drinkwater K.J. Radiotherapy management of muscle invasive bladder cancer: evaluation of a national cohort. Clin Oncol (R Coll Radiol) 2019;31(9):637–45. DOI:10.1016/j.clon.2019.04.009; Giacalone N.J., Shipley W.U., Clayman R.H. et al. Long‑term outcomes after bladderpreserving tri‑modality therapy for patients with muscle‑invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience. Eur Urol 2017;71(6):952–60. DOI:10.1016/j.eururo.2016.12.020; Francolini G., Borghesi S., Fersino S. et al. Treatment of muscle‑invasive bladder cancer in patients without comorbidities and fit for surgery: trimodality therapy vs radical cystectomy. Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) recommendation by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Crit Rev Oncol Hematol 2021;159:103235. DOI:10.1016/j.critrevonc.2021.103235; Kulkarni G.S., Hermanns T., Wei Y. et al. Propensity score analysis of radical cystectomy versus bladder‑sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic. J Clin Oncol 2017;35(20):2299–305. DOI:10.1200/JCO.2016.69.2327; Ding H., Fan N., Ning Z., Ma D. Trimodal therapy vs. radical cystectomy for muscleinvasive bladder cancer: a meta‑analysis. Front Oncol 2020;10:564779. DOI:10.3389/fonc.2020.564779; Deuker M., Krimphove M.J., Stolzenbach L.F. et al. Radical cystectomy vs. multimodality treatment in T2N0M0 bladder cancer: a population‑based, agematched analysis. Clin Genitourin Cancer 2021;19(4):e264–71. DOI:10.1016/j.clgc.2021.03.010; Pieretti A., Krasnow R., Drumm M. et al. Complications and outcomes of salvage cystectomy after trimodality therapy. J Urol 2021;206(1):29–36. DOI:10.1097/JU.0000000000001696; Клинические рекомендации. Рак мочевого пузыря. Министерство здравоохранения Российской Федерации, 2020. Доступно по: https://cr.minzdrav.gov.ru.; Pieters B.R., van der Steen‑Banasik E., Smits G.A. et al. GEC‑ESTRO/ACROP recommendations for performing bladdersparing treatment with brachytherapy for muscle‑invasive bladder carcinoma. Radiother Oncol 2017;122(3):340–6. DOI:10.1016/j.radonc.2016.12.022; Der Steen‑Banasik E.V., Oosterveld B., Smits G. et al. Perpetual role of brachytherapy in organ‑sparing treatment for bladder cancer: a historical review. J Contemp Brachytherapy 2020;12(6): 618–28. DOI:10.5114/jcb.2020.101697; Heidegger I., Oberaigner W., Horninger W., Pichler R. High incidence of clinically significant concomitant prostate cancer in patients undergoing radical cystectomy for bladder cancer: a 10‑year single‑center experience. Urol Oncol 2017;35(4):152.e1–5. DOI:10.1016/j.urolonc.2016.11.004; Kumar A., Cherry D.R., Courtney P.T. et al. Outcomes for muscle‑invasive bladder cancer with radical cystectomy or trimodal therapy in US veterans. Eur Urol Open Sci 2021;30:1–10. DOI:10.1016/j.euros.2021.05.009; Zhu Z., Zhao J., Li Y. et al. Prognostic value of preoperative hydronephrosis in patients with bladder cancer undergoing radical cystectomy: a meta‑analysis. PLoS One 2019;14(9):e0222223. DOI:10.1371/journal.pone.0222223; Krasnow R.E., Drumm M., Roberts H.J. et al. Clinical outcomes of patients with histologic variants of urothelial cancer treated with trimodality bladder‑sparing therapy. Eur Urol 2017;72(1):54–60. DOI:10.1016/j.eururo.2016.12.002; Bertz S., Wach S., Taubert H. et al. Micropapillary morphology is an indicator of poor prognosis in patients with urothelial carcinoma treated with transurethral resection and radiochemotherapy. Virchows Arch 2016;469(3):339–44. DOI:10.1007/s00428‑016‑1986‑x; Nagumo Y., Kojima T., Shiga M. et al. A single‑institute experience of trimodal bladder‑preserving therapy for histologic variants of urothelial carcinoma. Int J Clin Oncol 2020;25(2):354–61. DOI:10.1007/s10147‑019‑01553‑4; Khalifa J., Supiot S., Pignot G. et al. Recommendations for planning and delivery of radical radiotherapy for localized urothelial carcinoma of the bladder. Radiother Oncol 2021;161:95–114. DOI:10.1016/j.radonc.2021.06.011; Premo C., Apolo A.B., Agarwal P.K., Citrin D.E. Trimodality therapy in bladder cancer: who, what, and when? Urol Clin North Am 2015;42(2):169–80. DOI:10.1016/j.ucl.2015.02.002; Hindson B.R., Turner S.L., Millar J.L. et al. RANZCR Faculty of Radiation Oncology Genito‑Urinary Group (FROGG). Australian & New Zealand Faculty of Radia‑tion Oncology Genito‑Urinary Group: 2011 consensus guidelines for curative radiotherapy for urothelial carcinoma of the bladder. J Med Imaging Radiat Oncol 2012;56(1):18–30. DOI:10.1111/j.1754‑9485.2011.02336.x; Gofrit O.N., Meirovitz A., Frank S. et al. Trimodal therapy in T2–4aN0M0 bladder cancer – how to select the best candidate? Cancer Med 2020;9(22):8491–7. DOI:10.1002/cam4.3478; Huddart R.A., Birtle A., Maynard L. et al. Clinical and patient‑reported outcomes of SPARE – a randomised feasibility study of selective bladder preservation versus radical cystectomy. BJU Int 2017; 120(5): 639–50. DOI:10.1111/bju.13900; Freeman R.M. How urgent is urgency? A review of current methods of assessment. Int Urogynecol J Pelvic Floor Dysfunct 2005;16(2):93–5. DOI:10.1007/s00192‑004‑1253‑6; Feldman A.S., Kulkarni G.S., Bivalacqua T.J. et al. Surgical challenges and considerations in tri‑modal therapy for muscle invasive bladder cancer. Urol Oncol 2021:S1078–1439(21)00012–0. DOI:10.1016/j.urolonc.2021.01.013; Nguyen E.K., Yu H., Pond G. et al. Outcomes of trimodality bladder‑sparing therapy for muscle‑invasive bladder cancer. Can Urol Assoc J 2020;14(4):122–9. DOI:10.5489/cuaj.5945; Russell C.M., Lebastchi A.H., Borza T. et al. The Role of transurethral resection in trimodal therapy for muscle‑invasive bladder cancer. Bladder Cancer 2016;2(4):381–94. DOI:10.3233/BLC‑160076; Ouzaid I., Panthier F., Hermieu J.F., Xylinas E. Contemporary surgical and technical aspects of transurethral resection of bladder tumor. Transl Androl Urol 2019;8(1):21–4. DOI:10.21037/tau.2019.01.04; Russo G.I., Sholklapper T.N., Cocci A. et al. Performance of narrow band imaging (NBI) and photodynamic diagnosis (PDD) fluorescence imaging compared to white light cystoscopy (WLC) in detecting non‑muscle invasive bladder cancer: a systematic review and lesion‑level diagnostic meta‑analysis. Cancers (Basel) 2021;13(17):4378. DOI:10.3390/cancers13174378; Babjuk M., Burger M., Capoun O. et al. European Association of Urology guidelines on non‑muscle‑invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol 2021;81(1):75–94. DOI:10.1016/j.eururo.2021.08.010; Новиков А.И., Леоненков Р.В., Темкин Д.Б. и др. Трансуретральная резекция карциномы мочевого пузыря, распространяющейся на устье мочеточника. Онкоурология 2021;17(2):104–11. DOI:10.17650/1726‑9776‑2021‑17‑2104‑111; Hafeez S., Lewis R., Hall E., Huddart R. RAIDER trial management group. Advancing radiotherapy for bladder cancer: randomised phase II trial of adaptive image‑guided standard or dose‑escalated tumour boost radiotherapy (RAIDER). Clin Oncol (R Coll Radiol) 2021;33(6):e251–6. DOI:10.1016/j.clon.2021.02.012; Nolan C.P., Forde E.J. A review of the use of fiducial markers for image‑guided bladder radiotherapy. Acta Oncol 2016;55(5):533–8. DOI:10.3109/0284186X.2015.1110250; De Ridder M., Gerbrandy L.C., de Reijke T.M. et al. BioXmark® liquid fiducial markers for image‑guided radiotherapy in muscle invasive bladder cancer: a safety and performance trial. Br J Radiol 2020;93(1111):20200241. DOI:10.1259/bjr.20200241; Russell B., Liedberg F., Khan М.S. et al. Systematic review and meta‑analysis of delay in radical cystectomy and the effect on survival in bladder cancer patients. Eur Urol Oncol 2020;3(2):239–49. DOI:10.1016/j.euo.2019.09.008; Yin M., Joshi M., Meijer R.P. et al. Chemotherapy for muscle‑invasive bladder cancer: a systematic review and two‑step meta‑analysis. Oncologist 2016;21(6):708–15. DOI:10.1634/theoncologist.2015‑0440; Vale C.L. Advanced Bladder Cancer (ABC) Meta‑analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and metaanalysis of individual patient data advanced bladder cancer (ABC) meta‑analysis collaboration. Eur Urol 2005;48(2):202–6; discussion 205–6. DOI:10.1016/j.eururo.2005.04.006; Griffiths G., Hall R., Sylvester R. et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscleinvasive bladder cancer: long‑term results of the BA06 30894 trial. J Clin Oncol 2011;29(16):2171–7. DOI:10.1200/JCO.2010.32.3139; Kragelj B., Zaletel‑Kragelj L., Sedmak B. et al. Phase II study of radiochemotherapy with vinblastine in invasive bladder cancer. Radiother Oncol 2005;75(1):44–7. DOI:10.1016/j.radonc.2005.01.007; Tester W., Caplan R., Heaney J. et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 1996;14(1):119–26. DOI:10.1200/JCO.1996.14.1.119; Lin C.C., Hsu C.H., Cheng J.C. et al. Induction cisplatin and fluorouracil‑based chemotherapy followed by concurrent chemoradiation for muscle‑invasive blad‑der cancer. Int J Radiat Oncol Biol Phys 2009;75(2):442–8. DOI:10.1016/j.ijrobp.2008.11.030; Smith Z.L., Christodouleas J.P., Keefe S.M. et al. Bladder preservation in the treatment of muscle‑invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy. BJU Int 2013;112(1):13–25. DOI:10.1111/j.1464‑410X.2012.11762.x; Efstathiou J.A., Spiegel D.Y., Shipley W.U. et al. Long‑term outcomes of selective bladder preservation by combined‑modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 2012;61(4):705–11. DOI:10.1016/j.eururo.2011.11.010; Ajib K., Tjong M.C., Tan G.H. et al. Canadian experience of neoadjuvant chemotherapy on bladder recurrences in patients managed with trimodal therapy for muscle‑invasive bladder cancer. Can Urol Assoc J 2020;14(12):404–10. DOI:10.5489/cuaj.6459; Royce T.J., Liu Y., Milowsky M.I. et al. Trimodality therapy with or without neoadjuvant chemotherapy for muscle‑invasive bladder cancer. Clin Genitourin Cancer 2021;19(4):362–8. DOI:10.1016/j.clgc.2021.03.007; Mitin T., Dengina N., Chernykh M. et al. Management of muscle invasive bladder cancer with bladder preservation in Russia: a survey‑based analysis of current practice and the impact of an educational workshop on clinical expertise. J Cancer Educ 2021;36(5):1005–13. DOI:10.1007/s13187‑020‑01728‑y; Cowan R.A., McBain C.A., Ryder W.D. et al. Radiotherapy for muscle‑invasive carcinoma of the bladder: results of a randomized trial comparing conventional whole bladder with dose‑escalated partial bladder radiotherapy. Int J Radiat Oncol Biol Phys 2004;59(1):197–207. DOI:10.1016/j.ijrobp.2003.10.018; Huddart R.A., Hall E., Hussain S.A. et al. Randomized noninferiority trial of reduced high‑dose volume versus standard volume radiation therapy for muscle‑invasive bladder cancer: results of the BC2001 trial (CRUK/01/004). Int J Radiat Oncol Biol Phys 2013;87(2):261–9. DOI:10.1016/j.ijrobp.2013.06.2044; Nixon R.G., Chang S.S., Lafleur B.J. et al. Carcinoma in situ and tumor multifocality predict the risk of prostatic urethral involvement at radical cystectomy in men with transitional cell carcinoma of the bladder. J Urol 2002;167(2 Pt 1):502–5. DOI:10.1097/00005392‑200202000‑00012; Kefer J.C., Voelzke B.B., Flanigan R.C. et al. Risk assessment for occult malignancy in the prostate before radical cystectomy. Urology 2005;66(6):1251–5. DOI:10.1016/j.urology.2005.07.006; Stein J.P., Penson D.F., Wu S.D., Skinner D.G. Pathological guidelines for orthotopic urinary diversion in women with bladder cancer: a review of the litera‑ture. J Urol 2007;178(3 Pt 1):756–60. DOI:10.1016/j.juro.2007.05.013; Rödel C., Grabenbauer G.G., Kühn R. et al. Combined‑modality treatment and selective organ preservation in invasive bladder cancer: long‑term results. J Clin Oncol 2002;20(14):3061–71. DOI:10.1200/JCO.2002.11.027; Arcangeli G., Arcangeli S., Strigari L. A systematic review and meta‑analysis of clinical trials of bladder‑sparing trimodality treatment for muscle‑invasive bladder cancer (MIBC). Crit Rev Oncol Hematol 2015;94(1):105–15. DOI:10.1016/j.critrevonc.2014.11.007; Van Leeuwen C.M., Oei A.L., Crezee J. et al. The alfa and beta of tumours: a review of parameters of the linear‑quadratic model, derived from clinical radiotherapy studies. Radiat Oncol 2018;13(1):96. DOI:10.1186/s13014‑018‑1040‑z; Hoskin P.J., Rojas A.M., Bentzen S.M., Saunders M.I. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol 2010;28(33):4912–8. DOI:10.1200/JCO.2010.28.4950; James N.D., Hussain S.A., Hall E. et al. Radiotherapy with or without chemotherapy in muscle‑invasive bladder cancer. N Engl J Med 2012;366(16):1477–88. DOI:10.1056/NEJMoa1106106; Choudhury A., Swindell R., Logue J.P. et al. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle‑invasive bladder cancer. J Clin Oncol 2011;29(6):733–8. DOI:10.1200/JCO.2010.31.5721; Thompson C., Joseph N., Sanderson B. et al. Tolerability of concurrent chemoradiation therapy with gemcitabine (GemX), with and without prior neoadjuvant chemotherapy, in muscle invasive bladder cancer. Int J Radiat Oncol Biol Phys 2017;97(4):732–9. DOI:10.1016/j.ijrobp.2016.11.040; Hussain S.A., Stocken D.D., Peake D.R. et al. Long‑term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. Br J Cancer 2004;90(11):2106–11. DOI:10.1038/sj.bjc.6601852; Choudhury A., Porta N., Hall E. et al. Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta‑analysis of the BC2001 and BCON trials. Lancet Oncol 2021;22(2):246–55. DOI:10.1016/S1470‑2045(20)30607‑0; Zietman A.L., Grocela J., Zehr E. et al. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder. Urology 2001;58(3):380–5. DOI:10.1016/s0090‑4295(01)01219‑5; Pos F.J., Hart G., Schneider C., Sminia P. Radical radiotherapy for invasive bladder cancer: what dose and fractionation schedule to choose? Int J Radiat Oncol Biol Phys 2006;64(4):1168–73. DOI:10.1016/j.ijrobp.2005.09.023; Whalley D., Caine H., McCloud P. et al. Promising results with image guided intensity modulated radiotherapy for muscle invasive bladder cancer. Radiat Oncol 2015;10:205. DOI:10.1186/s13014‑015‑0499‑0; Murthy V., Gupta P., Baruah K. et al. Adaptive radiotherapy for carcinoma of the urinary bladder: long‑term outcomes with dose escalation. Clin Oncol (R Coll Radiol) 2019;31(9):646–52. DOI:10.1016/j.clon.2019.06.005; Hafeez S., Warren‑Oseni K., McNair H.A. et al. Prospective study delivering simultaneous integrated high‑dose tumor boost (≤70 Gy) with image guided adaptive radiation therapy for radical treatment of localized muscle‑invasive bladder cancer. Int J Radiat Oncol Biol Phys 2016;94(5):1022–30. DOI:10.1016/j.ijrobp.2015.12.379; Kibrom A.Z., Knight K.A. Adaptive radiation therapy for bladder cancer: a review of adaptive techniques used in clinical practice. J Med Radiat Sci 2015;62(4):277–85. DOI:10.1002/jmrs.129; Stein J.P., Lieskovsky G., Cote R. et al. Radical cystectomy in the treatment of invasive bladder cancer: long‑term results in 1,054 patients. J Clin Oncol 2001;19(3):666–75. DOI:10.1200/JCO.2001.19.3.666; Tunio M.A., Hashmi A., Qayyum A. et al. Whole‑pelvis or bladder‑only chemoradiation for lymph node‑negative invasive bladder cancer: single‑institution experience. Int J Radiat Oncol Biol Phys 2012;82(3):e457–62. DOI:10.1016/j.ijrobp.2011.05.051; Mari A., Kimura S., Foerster B. et al. A systematic review and meta‑analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens. BJU Int 2019;123(1):11–21. DOI:10.1111/bju.14417; Werntz R.P., Smith Z.L., Packiam V.T. et al. The impact of lymphovascular invasion on risk of upstaging and lymph node metastasis at the time of radical cystectomy. Eur Urol Focus 2020;6(2):292–7. DOI:10.1016/j.euf.2018.09.019; Goldsmith B., Baumann B.C., He J. et al. Occult pelvic lymph node involvement in bladder cancer: implications for definitive radiation. Int J Radiat Oncol Biol Phys 2014;88(3):603–10. DOI:10.1016/j.ijrobp.2013.11.211; Hall E., Hussain S.A., Porta N. et al. BC2001 long‑term outcomes: a phase III randomized trial of chemoradiotherapy versus radiotherapy (RT) alone and standard RT versus reduced high‑dose volume RT in muscle‑invasive bladder cancer. J Clin Oncol 2017;35:280. DOI:10.1200/JCO.2017.35.6_suppl.280; Джойнер М.С., ван дер Когель О.Д. Основы клинической радиобиологии. Гл. 18. Совместное применение лучевой и химиотерапии. Пер. с англ. М.: БИНОМ. Лаборатория знаний, 2013. 600 с.; Coen J.J., Zhang P., Saylor P.J. et al. Bladder preservation with twice‑a‑day radiation plus fluorouracil/cisplatin or once daily radiation plus gemcitabine for muscle‑invasive bladder cancer: NRG/RTOG 0712 – а randomized phase II trial. J Clin Oncol 2019;37(1):44–51. DOI:10.1200/JCO.18.00537; Гладков О. А., Зуков Р.А., Матвеев В. Б. и др. Практические рекомендации по лекарственному лечению рака мочевого пузыря. Злокачественные опухоли: Практические рекомендации RUSSCO 2021;11(32). DOI:10.18027/2224‑5057‑2021‑11‑3s2‑32; Portner R., Bajaj A., Elumalai T. et al. A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle‑invasive bladder cancer. Clin Transl Radiat Oncol 2021;31:1–7. DOI:10.1016/j.ctro.2021.08.003; Caffo O., Thompson C., De Santis M. et al. Concurrent gemcitabine and radiotherapy for the treatment of muscle‑invasive bladder cancer: a pooled individual data analysis of eight phase I–II trials. Radiother Oncol 2016;121(2):193–8. DOI:10.1016/j.radonc.2016.09.006; Wettstein M.S., Rooprai J.K., Pazhepurackel C. et al. Systematic review and meta‑analysis on trimodal therapy versus radical cystectomy for muscleinvasive bladder cancer: does the current quality of evidence justify definitive conclusions? PLoS One 2019;14(4):e0216255. DOI:10.1371/journal.pone.0216255; Mak R.H., Hunt D., Shipley W.U. et al. Long‑term outcomes in patients with muscleinvasive bladder cancer after selective bladder‑preserving combined‑modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol 2014;32(34):3801–9. DOI:10.1200/JCO.2014.57.5548; Bladder cancer: diagnosis and management of bladder cancer: ©NICE (2015) Bladder cancer: diagnosis and management of bladder cancer. BJU Int 2017;120(6):755–65. DOI:10.1111/bju.14045; Payne H., Adamson A., Bahl A. et al. Chemicaland radiation‑induced haemorrhagic cystitis: current treatments and challenges. BJU Int 2013;112(7):885– 97. DOI:10.1111/bju.12291; Kool R., Marcq G., El‑Achkar A. et al. Refining assessment of response to radiation‑based therapy for muscleinvasive bladder cancer: is post‑treatment tumor bed biopsy always necessary? Urol Oncol 2021;39(5):299.e7–14. DOI:10.1016/j.urolonc.2020.10.001; Spencer K., Jones C.M., Girdler R. et al. The impact of the COVID‑19 pandemic on radiotherapy services in England UK: a population‑based study. Lancet Oncol 2021;22(3):309–20. DOI:10.1016/S1470‑2045(20)30743‑9; Mitin T., Choudhury A. The role of biomarkers in bladder preservation management of muscle‑invasive bladder cancer. World J Urol 2019;37(9):1767–72. DOI:10.1007/s00345‑018‑2480‑7; Wu C.T., Chen W.C., Chang Y.H. et al. The role of PD‑L1 in the radiation response and clinical outcome for bladder cancer. Sci Rep 2016;6:19740. DOI:10.1038/srep19740; https://oncourology.abvpress.ru/oncur/article/view/1534
-
6Academic Journal
Source: Health of Man; No. 3 (2021); 109-114
Здоровье мужчины; № 3 (2021); 109-114
Здоров'я чоловіка; № 3 (2021); 109-114Subject Terms: safety, метастазування, complications, efficacy, выживаемость, partial cystectomy, лимфоррея, muscle invasive bladder cancer, survival, 03 medical and health sciences, 0302 clinical medicine, органосохраняющая операция, виживаність, metastasis, осложнения, мышечно-инвазивный рак мочевого пузыря, ефективність, тазова лімфаденектомія, органозберігаюча операція, лімфорея, эффективность, 616.62-006.6-089, м'язево-інвазивний рак сечового міхура, organ-sparing surgery, метастазирование, безопасность, ускладнення, pelvic lymph node dissection, 3. Good health, парціальна цистектомія, тазовая лимфаденэктомия, lymphorrhea, безпечність, парциальная цистэктомия
File Description: application/pdf
Access URL: http://health-man.com.ua/article/view/246218
-
7Academic Journal
Authors: Yakovlev , P. G.
Source: Hospital Surgery. Journal named by L.Ya. Kovalchuk; No. 2 (2019); 28-33 ; Госпитальная хирургия. Журнал имени Л.А. Ковальчука; № 2 (2019); 28-33 ; Шпитальна хірургія. Журнал імені Л. Я. Ковальчука; № 2 (2019); 28-33 ; 2414-4533 ; 1681-2778 ; 10.11603/2414-4533.2019.2
Subject Terms: muscle-invasive bladder cancer, radical cystectomy, organ sparing surgery, trimodality treatment, overall survival, мышечно-инвазивный рак мочевого пузыря, радикальная цистэктомия, органосохраняющая операция, тримодальная терапия, общая выживаемость, м’язово-інвазивний рак сечового міхура, радикальна цистектомія, органозберігальна операція, тримодальна терапія, загальна виживаність
File Description: application/pdf
Relation: https://ojs.tdmu.edu.ua/index.php/surgery/article/view/10415/9974; https://ojs.tdmu.edu.ua/index.php/surgery/article/view/10415; https://repository.tdmu.edu.ua//handle/123456789/13324
-
8Academic Journal
Authors: Vozianov, S.O., Sakalo, V.S., Gatserelia, Z.V., Mrachkovskyi, V.V., Sakalo, A.V., Kuranov, Yu.Yu., Kondratenko, A.V., Salii, P.M., Levchyshyn, Ya.V., Navrotskyi, B.M.
Source: Urologiya; Том 24, № 3 (2020)
Урология; Том 24, № 3 (2020)
Урологія; Том 24, № 3 (2020)Subject Terms: 2. Zero hunger, 03 medical and health sciences, 0302 clinical medicine, органосохраняющее лечение, мышечно-инвазивный рак мочевого пузыря, химиолучевая терапия, органозберігаюче лікування, м'язево-інвазивний рак сечового міхура, хіміопроменева терапія, organ-preserving treatment, muscular-invasive bladder cancer, chemoradiation therapy, 3. Good health
File Description: application/pdf
-
9Academic Journal
Authors: М. И. Волкова, М. М. Тхакохов, В. А. Черняев, К. М. Фигурин, В. А. Романов, С. А. Калинин, М. В. Петерс, О. И. Евсюкова, В. Б. Матвеев
Contributors: нет
Source: Cancer Urology; Том 12, № 4 (2016); 131-141 ; Онкоурология; Том 12, № 4 (2016); 131-141 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2016-12-4
Subject Terms: уретерогидронефроз, трансуретральная резекция, открытая резекция мочевого пузыря, мышечно-инвазивный рак мочевого пузыря, лучевая терапия, химиотерапия, радикальная цистэктомия, цистэктомия спасения, микроцистис
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/629/614; Mak R.H., Zietman A.L., Heney N.M. et al. Bladder preservation: optimizing radiotherapy and integrated treatment strategies. BJU Int 2008;102(9 Pt B):1345–53. DOI:10.1111/j.1464-410X.2008.07981.x. PMID: 19035903.; Shipley W.U., Kaufman D.S., Zehr E. et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002;60(1):62–7; discussion 67–8. PMID: 12100923.; Shipley W.U., Winter K.A., Kaufman D.S. et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89–03. J Clin Oncol 1998;16(11):3576–83. DOI:10.1200/jco.1998.16.11.3576. PMID: 9817278.; Efstathiou J.A., Bae K., Shipley W.U. et al. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol 2009;27(25):4055–61. DOI:10.1200/JCO.2008.19.5776. PMID: 19636019.; Eswara J.R., Efstathiou J.A., Heney N.M. et al. Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer. J Urol 2012;187(2):463–8. DOI:10.1016/j.juro.2011.09.159. PMID: 22177159.; Nieuwenhuijzen J.A., Horenblas S., Meinhardt W. Salvage cystectomy after failure of interstitial radiotherapy and external beam radiotherapy for bladder cancer. BJU Int 2004;94(6):793–7. DOI:10.1111/j.1464-410X.2004.05034.x. PMID: 15476510.; Bochner B.H., Figueroa A.J., Skinner E.C. et al. Salvage radical cystoprostatectomy and orthotopic urinary diversion following radiation failure. J Urol 1998;160(1):29–33. PMID: 9628599.; Srikishen N., Abreu A., Aghazadeh M. Robotic salvage cystectomy is safe: multiinstitutional perioperative outcomes. AUA 2015. Abstract: PD31–04.; Gschwend J.E., May F., Paiss T. et al. High-dose pelvic irradiation followed by ileal neobladder urinary diversion: complications and long-term results. Br J Urol 1996;77(5):680–3. PMID: 8689110.; Eisenberg Dorin R.P. Bartsch G. et al. Early complications of cystectomy after high dose pelvic radiation. J Urol 2010;184(6):2264–9. DOI:10.1016/j.juro.2010.08.007. PMID: 20952024.; Ahlering T.E., Lieskovsky G., Skinner D.G. Salvage surgery plus androgen deprivation for radioresistant prostatic adenocarcinoma. J Urol 1992;147(3 Pt 2):900–2. PMID: 1538492.; Blandy J.P., England H.R., Evans S.J. et al. T3 bladder cancer – the case for salvage cystectomy. Br J Urol 1980;52(6):506–10. PMID: 7459580.; Lund F. Cystectomy following full course irradiation//in bladder tumors and other topics in urological oncology. Ettore Majorana International Science Series. Vol. 1, 1980. Pp. 287–289.; Edsmyr F., Moberger G., Wadstrom L. Carcinoma of the bladder. Cystectomy after supervoltage therapy. Scand J Urol Nephrol 1971;5(3):215–21. PMID: 4998747.; Crawford E.D., Skinner D.G. Salvage cystectomy after irradiation failure. J Urol 1980;123(1):32–4.; Swanson D.A., von Eschenbach A.C., Bracken R.B., Johnson D.E. Salvage cystectomy for bladder carcinoma. Cancer 1981;47(1):2275–9. PMID: 7226122.; Smith J.A., Whitmore W.F. Regional lymph node metastases from bladder cancer. Urol 1981;126(5):591–3. PMID: 7299915.; Abratt R.P., Wilson J.A., Pontin A.R., Barnes RD. Salvage cystectomy after radical irradiation for bladder cancer–prognostic factors and complications. Br J Urol 1993;72(5 Pt 2):756–60. PMID: 8281409.; Konnak J.W., Grossman H.B. Salvage cystectomy following failed definitive radiation therapy for transitional cell carcinoma of bladder. Urology 1985;26(6):550–3. PMID: 3934829.; Матвеев В.Б., Волкова М.И. Рак мочевого пузыря. Проблемы клинической медицины 2006;(4):10–5. [Matveev V.B., Volkova M.I. Bladder cancer. Problemy klinicheskoy meditsiny = Problems of Clinical Medicine 2006;(4):10–5. (In Russ.)].; https://oncourology.abvpress.ru/oncur/article/view/629; undefined
Availability: https://oncourology.abvpress.ru/oncur/article/view/629
-
10Academic Journal
Source: Onkourologiâ, Vol 12, Iss 4, Pp 131-141 (2016)
Subject Terms: рак мочевого пузыря, трансуретральная резекция, открытая резекция мочевого пузыря, мышечно-инвазивный рак мочевого пузыря, лучевая терапия, химиотерапия, радикальная цистэктомия, цистэктомия спасения, микроцистис, уретерогидронефроз, Medicine
-
11Academic Journal
Authors: В.М. Попков, Андрей Николаевич Понукалин, Н.Б. Захарова
Subject Terms: мышечно-инвазивный рак мочевого пузыря, фактор роста эндотелия сосудов, сыворотка, плазма, диагностический фактор, прогностический фактор
File Description: text/html
-
12Academic Journal
РОЛЬ «ВКЛЮЧЕНИЯ И ВЫКЛЮЧЕНИЯ» АНГИОГЕНЕЗА У БОЛЬНЫХ МЫШЕЧНО-ИНВАЗИВНЫМ РАКОМ МОЧЕВОГО ПУЗЫРЯ (МИРМП)
Authors: ПОНУКАЛИН А.Н., ЗАХАРОВА Н.Б.
Subject Terms: МЫШЕЧНО-ИНВАЗИВНЫЙ РАК МОЧЕВОГО ПУЗЫРЯ
File Description: text/html
-
13Academic Journal
Authors: Скрипцова, С.
Subject Terms: АНГИОГЕНЕЗ, ФРЭС, МЫШЕЧНО-ИНВАЗИВНЫЙ РАК МОЧЕВОГО ПУЗЫРЯ (МИРМП)
File Description: text/html
-
14Academic Journal
Authors: Понукалин, А., Маслякова, Г., Цмокалюк, Е.
Subject Terms: МЫШЕЧНО-ИНВАЗИВНЫЙ РАК МОЧЕВОГО ПУЗЫРЯ, СТАДИРОВАНИЕ И ПРОГНОЗ
File Description: text/html
-
15Academic Journal
Source: Онкоурология.
Subject Terms: 03 medical and health sciences, 0302 clinical medicine, 3. Good health, мышечно-инвазивный рак мочевого пузыря, фактор роста эндотелия сосудов, сыворотка, плазма, диагностический фактор, прогностический фактор
File Description: text/html
-
16Academic Journal
Authors: Лелявин, К.
Subject Terms: МЫШЕЧНО-ИНВАЗИВНЫЙ РАК МОЧЕВОГО ПУЗЫРЯ, РАДИКАЛЬНАЯ ЦИСТЭКТОМИЯ, КИШЕЧНАЯ ПЛАСТИКА, ВЫЖИВАЕМОСТЬ
File Description: text/html
-
17Academic Journal
Authors: Гуменецкая, Ю., Попов, А., Карякин, О., Гулидов, И.
Subject Terms: МЫШЕЧНО-ИНВАЗИВНЫЙ РАК МОЧЕВОГО ПУЗЫРЯ, ХИМИОЛУЧЕВАЯ ТЕРАПИЯ
File Description: text/html
-
18Academic Journal
Authors: Попков, В., Понукалин, А., Захарова, Н.
Subject Terms: МЫШЕЧНО-ИНВАЗИВНЫЙ РАК МОЧЕВОГО ПУЗЫРЯ, ОНКОМАРКЕРЫ, ФАКТОР РОСТА ЭНДОТЕЛИЯ СОСУДОВ, ЦИТОКЕРАТИНЫ
File Description: text/html
-
19Academic Journal
Authors: Русаков, И., Головащенко, М.
File Description: text/html
-
20Academic Journal
Authors: Лелявин, Кирилл
Subject Terms: МЫШЕЧНО-ИНВАЗИВНЫЙ РАК МОЧЕВОГО ПУЗЫРЯ, РАДИКАЛЬНАЯ ЦИСТЭКТОМИЯ, КИШЕЧНАЯ ПЛАСТИКА, ДЕРИВАЦИЯ МОЧИ
File Description: text/html
